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Abstract
BACKGROUND: Neuroinflammation is an important secondary injury mechanism that contributes to neurological 
impairments after traumatic brain injury (TBI). There is a robust evidence that neuroinflammation will diminish 
neurogenesis after TBI. Therefore, strategies to attenuate the inflammatory responses are potential to increase 
neurogenesis following TBI. Minocycline, a second-generation tetracycline antibiotic derivate, has potent anti-
inflammatory effect by reducing microglial activation and suppressing some pro-inflammatory cytokines. 
AIM: The aim of this study is to investigate if minocycline could enhance neurogenesis after TBI. 
METHODS: Thirty Sprague Dawley rats were randomized into three treatments group, i.e., sham-operated controls, 
closed head injury (CHI), and CHI with minocycline. We used the modified Feeney’s weight-drop model for making CHI. 
For the treatment group, we gave minocycline per oral (50 mg/kg) twice daily for the first 2 days followed by 25 mg/
kg once daily for 3 consecutive days. Animals were sacrificed on day 5. To assess the proliferation capacity of neural 
stem cells (NSC), we performed immunohistochemistry staining with SOX2, brain-derived neurotropic factor (BDNF), 
and NFR. Cell counts were carried out using light microscope with 1000 times magnification in 20 high-power fields.
RESULTS: SOX2, NF-E2-related factor 2 (NRF-2), and BDNF were upregulated in the CHI group compared to 
the sham-operated group (p < 0.05). NRF-2, BDNF, and SOX2 were upregulated also significantly in the CHI+ 
minocycline group compared to the sham-operated group and the CHI group (p < 0.05). 
CONCLUSION: Minocycline increased the proliferation capacity of NSC.
Edited by: Mirko Spiroski
Citation: Indharty RRS, Japardi I, Siahaan AMP, 
Tandean S, Loe ML. Efficacy of Minocycline in Neural 
Stem Cells Proliferation after Traumatic Brain Injury. 
Open Access Maced J Med Sci. 2020 Mar 25; 8(A):59-64. 
https://doi.org/10.3889/oamjms.2020.3875
Keywords: Brain-derived neurotropic factor; Minocycline; 
Neurogenesis; NF-E2-related factor 2; Traumatic brain 
injury; SOX2
*Correspondence: R. R. Suzy Indharty, Department of 
Neurosurgery, School of Medicine, Universitas Sumatera 
Utara, Haji Adam Malik General Hospital, Medan, 
Indonesia. E-mail: rrsuzyi@yahoo.com
Received: 11-Oct-2019
Revised: 21-Jan-2020
Accepted: 06-Mar-2020
Copyright: © 2020 R. R. Suzy Indharty, Iskandar 
Japardi, Andre M. P. Siahaan, Steven Tandean, 
Michael Lumintang Loe
Funding: This research did not receive any financial 
support
Competing Interests: The authors have declared that no 
competing interest exists
Open Access: This is an open-access article distributed 
under the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 4.0)
Introduction
Neurogenesis is the process of developing 
new neural cells from multipotent cells. Formerly, this 
process was believed to happen only during embryonic 
development. At present, it is generally accepted that 
neurogenesis can also happen in the adult brain, i.e., in 
the subgranular zone (SGZ) in the dentate gyrus (DG) 
of the hippocampus, as well as the subventricular 
zone lining the lateral ventricles. Neural stem cells 
(NSCs) are the multipotent cells that will proliferate 
and migrate to the granule cell layer in the DG. In DG, 
the NSCs will differentiate into neurons, astrocytes, or 
oligodendrocytes. The neurons then project into the 
hippocampus and become fully functional, integrated 
into the brain circuit [1], [2]. The neurogenesis process 
itself depends on a complicated microenvironment 
that requires multiple signaling between multiple cell 
types [3].
Traumatic brain injury (TBI) remains one of 
the most prominent causes of mortality and morbidity, 
especially in the young population [4]. TBI itself is a 
complex process, not just a single pathophysiological 
event [5]. The initial primary injury was followed by 
secondary injury that involves various pathways, 
including profound cerebral inflammation, excitatory 
amino acids and calcium associated cytotoxicity, 
and ischemic events. These injuries are seen as the 
cause of the development of neurological deficits 
after TBI [6].
Neuroinflammation is an important secondary 
injury mechanism that contributes to ongoing 
neurodegeneration and neurological impairments after 
TBI. Post-traumatic neuroinflammation is characterized 
by microglial activation, leukocyte recruitment, 
and upregulation of inflammatory mediators [7]. 
Neuroinflammation can play dual opposing roles. On 
the one hand, neuroinflammation will support repair 
and regeneration processes. On the other hand, it 
could exacerbate tissue damage. Microglial activation 
associated with neural inflammation diminishes 
neurogenesis in the hippocampus [8]. Interleukin 6, 
one of the inflammatory mediators, decreases the 
neurogenesis by more than half in the DG. Prolonged 
mitochondrial dysfunction was correlated with long-term 
diseases, such as Alzheimer’s disease [9]. Therefore, 
strategies to mitigate the inflammatory responses 
are potential to decrease neuron death and increase 
neurogenesis following TBI [10].
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Minocycline is a second-generation tetracycline 
antibiotic derivate that can cross the blood–brain 
barrier [11]. It is very crucial since the blood–brain 
barrier prevents the most type of chemicals from 
moving from the bloodstream into the central nervous 
system (CNS) [12]. Minocycline has been used in 
numerous neurological disorders, such as spinal 
cord injury [13], [14], ischemic brain injury [15], [16], 
Parkinson [17], and TBI [14], [18], [19]. Even the 
mechanism of neuroprotective effect of minocycline 
has not been fully elucidated, one of the most proposed 
mechanisms is an anti-inflammatory effect. Minocycline 
has potent anti-inflammatory effect by reducing microglial 
activation [20], [21], [22] and suppressing the generation 
of some pro-inflammatory cytokines [21], [23], [24].
Methods
Mouse model of closed head injury (CHI)
Thirty Sprague Dawley rats weighing 
250–400 g were randomized into three treatment 
groups, i.e., sham-operated controls, CHI, and CHI 
with minocycline (CHI+minocycline). All animals 
were given ketamine HCl (100 mg/kg, intramuscular) 
as an anesthetic agent. The scalp was cleaned 
with povidone-iodine and aseptic techniques were 
utilized throughout the surgery. The scalp was 
opened on the right frontal. Then, the rats were 
placed securely in stereotactic apparatus. We used 
modified Feeney’s drop model protocol to induce 
brain injury (20). A 40 mg metal mass was dropped 
from a height of 1.5 m, onto the right side of the 
head (Figure 1a). The brains were then removed 
(Figure 1b) and fixed in 10% formalin. The specimens 
were subsequently processed for paraffin embedded 
for immunohistochemistry staining. Sham-operated 
mice underwent anesthesia and surgery, without 
trauma and treatment.
Minocycline treatment protocol
Mice were given minocycline per oral 50 mg/kg 
daily for the 1st day followed by 25 mg/kg once daily for 
consecutive 4 days (5 days total) [8].
Immunohistochemistry staining
As a neurogenesis marker, we investigated 
the expression of the sex-determining region of the Y 
chromosome (Sry)-related high mobility group box2 (SOX2 
antibody (E-4): sc-365823; St. Cruz), NF-E2-related factor 
2 (NRF2 antibody [A-10]: sc-365949; St. Cruz), and 
mature brain-derived neurotropic factor (BDNF) (BDNF 
antibody [N-20]: sc-546; St. Cruz). The expression of all 
markers was investigated on paraffin-embedded sections 
using the avidin-biotin-peroxidase complex method. 
Five millimeters thick paraffin sections were dewaxed, 
rehydrated, and microwaved for 10 min. The endogenous 
peroxidase activity of the investigated specimens was 
blocked with 3% H2O2 for 10 min, followed by 25 min of 
washing with phosphate-buffered saline (PBS).
Figure 2: Mice brain after removal. (a) Closed head injury (CHI) 
group. (b) Negative sham group. (c) CHI+minocycline group
a cb
The tissue sections were incubated with normal 
rabbit serum for 10 min, and then, the slides were incubated 
at room temperature with monoclonal mouse anti-human 
SOX2, NRF, and BDNF (Santa Cruz). Sections were washed 
with PBS and incubated with a secondary antibody for 
30 min. Sections were washed twice with PBS, developed 
with 0.05% 3,3-diamino-benzinetetrahydrochloride for 
5 min, and slightly counterstained.
Figure 3: Expression of SOX2, brain-derived neurotropic factor, and 
NF-E2-related factor 2 in every group of brain tissues 5 days after 
closed head injury
Figure 1: Animal model. (a) Weight drop after craniotomy. (b) Brain 
removal after craniocervical dislocation
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All samples were evaluated by one pathologist 
(blinded) and first author (not blinded to specimen). 
Positive signal for SOX2, NRF, and BDNF was located 
in the nucleus of brain cells and the stainability was 
quantitatively estimated on the basis of the distribution 
of positively stained cells in the DG. Cell counts were 
carried out using a light microscope with 1000 times 
magnification in 20 high-power fields.
Statistical analysis
Total stained cells were reported as mean and 
standard deviation. When comparisons were made 
between groups, significance between-group variability 
was analyzed using the one-way ANOVA test with Tukey 
as post hoc test with JASP vers. 0.8.4. Differences were 
considered statistically significant at p < 0.05.
Results
Thirty rats were included in this research, 
divided into three groups, i.e., sham-operated controls, 
CHI, and CHI+minocycline. Minocycline was given 
consecutively in 5 days. During the follow-up, two rats 
died directly after trauma procedure. The brain was 
removed after craniocervical dislocation (Figure 2).
SOX2, NRF-2, and BDNF were upregulated 
in TBI
Immunohistochemistry was used to detect 
the expression of SOX2, NRF-2, and BDNF in brain 
tissue 5 days after CHI. As expected, SOX2, NRF-
2, and BDNF were localized to the nucleus. All of the 
immunopositive cells were found to be present in the 
DG, as well as generally in the brain parenchyma 
(Figure 3). Immunopositive cells to SOX2 in sham-
operated controls were 2.44 ± 1.01. Meanwhile, it was 
8.56 ±1.24 in the CHI group. Immunopositive cells to 
NRF-2 in sham-operated controls and CHI were 3.33 
±1.22 and 9.89 ± 2.26, respectively. Immunopositive 
cells to BDNF in sham-operated controls were 7.33 ± 
1.23 and in CHI were 9.78 ±1.56. We found that SOX2, 
NRF-2, and BDNF were significantly upregulated in the 
CHI group compared to the sham-operated group (p < 
0.05; Table 1).
Minocycline modulated the expression of 
transcription factor NRF-2
After the systemic administration of 
minocycline, it showed that minocycline modulated the 
expression of transcription factor NRF-2. The mean 
of immunopositive cells to NRF-2 was 12.67 ± 1.80 
(Figure 4). Immunohistochemistry showed that NRF-2 
was significantly upregulated in the CHI+minocycline 
group compared to the sham-operated group and the 
CHI group (p < 0.05; Table 1).
Table 1: Expression of SOX2, NRF-2, and m-BDNF in negative 
sham, CHI, and CHI+minocycline groups
Group SOX2 NRF BDNF
Negative sham 2.44±1.01 3.33±1.22 7.33±1.23
CHI 8.56±1.24 9.89±2.26 9.78±1.56
CHI+minocycline 11.67±1.94 12.67±1.80 12.00±1.22
p 0.0001 0.0001 0.0001
One-way ANOVA; *significant. CHI: Closed head injury, NRF-2: NF-E2-related factor 2, m-BDNF: m-brain-
derived neurotropic factor.
Figure 4: Expression of NF-E2-related factor 2 in brain tissue 5 days 
after
Minocycline upregulated the expression of 
BDNF
After the systemic administration of minocycline, 
it was shown that minocycline also modulated the 
expression of BDNF. Mean of immunopositive cells to 
BDNF was 12.00 ± 1.22 (Figure 5). We found that the 
number of cells labeled with BDNF was significantly 
increased in the CHI+minocycline group compared to 
the sham-operated group as well as the CHI group 
(p < 0.05, Table 1).
Figure 5: Expression of brain-derived neurotropic factor in brain 
tissue 5 days after closed head injury
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Minocycline increased the proliferation 
capacity of NSC
To assess the proliferation capacity of NSC, we 
studied the expression of SOX2. Immunohistochemistry 
showed that the expression of SOX2 was upregulated 
at 5 days in the CHI+minocycline group (Mean: 11.67 
± 1.94) (Figure 6). In the sham-operated group, fewer 
cells stained by SOX2 were seen in the DG as well 
as in the brain parenchyma. In the CHI group, the 
number of cells stained by SOX2 was increased in 
the DG. The number of cells labeled with SOX2 in the 
CHI+minocycline group was significantly increased 
compared to the sham-operated group and the CHI 
group (p < 0.05; Table 1).
of minocycline in neural injury therapy since the 
mobilization of NSCs is associated with better functional 
recovery from motor deficits [33], with the degree of 
behavioral recovery correlating with the number of stem 
cells surviving to reach the target tissue [34].
BDNF and NGF are well-characterized 
neurotrophins involved in the differentiation and 
survival of a number of neurons localized in the 
peripheral and CNS [35]. BDNF has important roles 
for neuroblast migration, survival, and integration of 
neurogenesis in the SVZ. The study using mice with a 
deletion of BDNF following TBI showed an escalation 
of newborn neuron death. Thus, BDNF plays a critical 
role in promoting the survival and integration of NSPC-
derived newborn neuron into neural circuitry [35]. We 
found that minocycline could significantly upregulate 
the expression of BDNF in the SGZ of the DG of the 
hippocampus.
Using immunohistochemistry, we found that 
NRF-2 was significantly upregulated in the CHI group 
compared to the sham-operated group (p < 0.05). 
All of this indicated that NRF-2 protein levels in the 
DG were raised after TBI. The previous research 
showed that TBI will activate the NRF2/antioxidant 
response element (ARE) pathway and increase the 
activity of NRF-2 transcription regulation. However, 
the regulation only increased the NRF-2 protein level 
but showed no change in the NRF-2 mRNA level. 
The NRF2/ARE pathway in TBI has an important 
neuroprotective role by inhibiting inflammatory 
cytokines and oxidative stress injuries. Two important 
antioxidases in the downstream of NRF2/ARE 
pathway are HO-1 and NQO1. HO-1 can produce 
dehydrobilirubin by catalyzing hematoma and 
decreasing the generation of free radicals. NQO1 can 
catalyze the reduction of two electrons and degrade 
quinones and its ramification to prevent participation 
in the reduction-oxidation reaction [36].
In this study, the NRF-2 level of CHI+minocycline 
was significantly increased compared to the CHI group, 
as was the SOX2 level. These results showed that 
minocycline administration increased NRF-2 levels after 
traumatic injury and promoted the proliferation of NSCs. 
The proliferation of NSCs was proved by an increase in 
SOX2 levels. SOX2 has an important role for referring 
the differentiation and maintaining the properties of 
NSCs [37]. Increased NRF-2 levels will mediate the 
induction of glutamate-cysteine ligase modifier subunit 
(GCLM) and enhance binding of AREs in the promoter 
region of its target genes. These conditions will activate 
multiple cell survival mechanisms through antioxidant, 
anti-inflammatory, and other cytoprotective pathways. 
NRF-2 was reportedly reduced in an intracellular redox 
state and reactive oxygen species, thus promoting cell 
proliferation and survival. With its roles, NRF-2 has 
been related to cell growth, self-renewal, mitosis, and 
prolonged lifespan, which are definitely associated with 
NSC functions [38].
Figure 6: Expression of SOX2 in brain tissue 5 days after closed head 
injury
Discussion
We investigated the effects of minocycline, a 
promising agent for treat TBI in the “acute phase,” on 
endogenous NSCs in vivo using immunohistochemistry. 
Our data suggest a positive effect of minocycline on NSC 
proliferation in the SGZ of the DG of the hippocampus.
Minocycline is a second-generation, 
semi-synthetic tetracycline analog which has anti-
inflammatory, immunomodulatory, and neuroprotective 
activities [25], [26]. Minocycline has been studied 
from a variety of experiments in neurological 
disorders, including hypoxic-ischemic injury [27], 
focal ischemia [16], Huntington’s disease [28], and 
amyotrophic lateral sclerosis [29]. Several mechanisms 
of action have been described to account for this effect, 
including anti-inflammatory [30] and antiapoptotic 
properties [31], as well as the inhibition of both 
polyadenosine diphosphate ribose polymerase-1 and 
matrix metalloproteinases [32].
Our finding that minocycline has positive 
effects on NSC numbers confirms and extends 
previous findings, suggesting clinically useful properties 
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Conclusion
This study provided data that minocycline 
administration increased the expression of NSCs 
following TBI. To the best of our knowledge, this is the 
first study to demonstrate the effect of minocycline 
in TBI. There were two main limitations of this study. 
First, it did not demonstrate how minocycline could 
increase stem cell expression, and second, there 
was no comparison regarding clinical outcome in the 
animals. Further investigations should be considered. 
In conclusion, minocycline is a promising candidate 
in TBI therapy, as it has a direct positive effect on the 
proliferation of endogenous NSCs in vivo.
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